These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 21699729

  • 1. Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension.
    Kosanovic D, Kojonazarov B, Luitel H, Dahal BK, Sydykov A, Cornitescu T, Janssen W, Brandes RP, Davie N, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Schermuly RT.
    Respir Res; 2011 Jun 23; 12(1):87. PubMed ID: 21699729
    [Abstract] [Full Text] [Related]

  • 2. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
    Behringer A, Trappiel M, Berghausen EM, Ten Freyhaus H, Wellnhofer E, Odenthal M, Blaschke F, Er F, Gassanov N, Rosenkranz S, Baldus S, Kappert K, Caglayan E.
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr 23; 389(4):369-79. PubMed ID: 26742933
    [Abstract] [Full Text] [Related]

  • 3. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
    Schäfer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, Kast R, Klein M.
    Cardiovasc Res; 2009 Apr 01; 82(1):30-9. PubMed ID: 19131365
    [Abstract] [Full Text] [Related]

  • 4. Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.
    Liu H, Liu ZY, Guan Q.
    Interact Cardiovasc Thorac Surg; 2007 Oct 01; 6(5):608-13. PubMed ID: 17670742
    [Abstract] [Full Text] [Related]

  • 5. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
    Yang PS, Kim DH, Lee YJ, Lee SE, Kang WJ, Chang HJ, Shin JS.
    Respir Res; 2014 Nov 25; 15():148. PubMed ID: 25420924
    [Abstract] [Full Text] [Related]

  • 6. Endothelin A receptor blockade improves regression of flow-induced pulmonary vasculopathy in piglets.
    Mercier O, Sage E, Izziki M, Humbert M, Dartevelle P, Eddahibi S, Fadel E.
    J Thorac Cardiovasc Surg; 2010 Sep 25; 140(3):677-83. PubMed ID: 20723731
    [Abstract] [Full Text] [Related]

  • 7. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
    Leong ZP, Okida A, Higuchi M, Yamano Y, Hikasa Y.
    Vascul Pharmacol; 2018 Jan 25; 100():41-50. PubMed ID: 29100963
    [Abstract] [Full Text] [Related]

  • 8. Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade.
    Jasmin JF, Cernacek P, Dupuis J.
    Clin Sci (Lond); 2003 Dec 25; 105(6):647-53. PubMed ID: 12823096
    [Abstract] [Full Text] [Related]

  • 9. Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
    Leong ZP, Hikasa Y.
    Vascul Pharmacol; 2018 Nov 25; 110():31-41. PubMed ID: 30071297
    [Abstract] [Full Text] [Related]

  • 10. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
    Porvasnik SL, Germain S, Embury J, Gannon KS, Jacques V, Murray J, Byrne BJ, Shacham S, Al-Mousily F.
    J Pharmacol Exp Ther; 2010 Aug 25; 334(2):364-72. PubMed ID: 20430844
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension.
    Kato T, Nasu T, Sonoda H, Ito KM, Ikeda M, Ito K.
    J Cardiovasc Pharmacol; 2008 Jan 25; 51(1):18-23. PubMed ID: 18209564
    [Abstract] [Full Text] [Related]

  • 12. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats.
    Nishida M, Hasegawa Y, Tanida I, Nakagawa E, Inaji H, Ohkita M, Matsumura Y.
    Eur J Pharmacol; 2009 Jul 01; 614(1-3):70-6. PubMed ID: 19379725
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of right coronary vascular dysfunction in severe pulmonary hypertensive rats using synchrotron radiation microangiography.
    Inagaki T, Pearson JT, Tsuchimochi H, Schwenke DO, Saito S, Higuchi T, Masaki T, Umetani K, Shirai M, Nakaoka Y.
    Am J Physiol Heart Circ Physiol; 2021 Mar 01; 320(3):H1021-H1036. PubMed ID: 33481696
    [Abstract] [Full Text] [Related]

  • 14. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
    Rocchetti M, Sala L, Rizzetto R, Staszewsky LI, Alemanni M, Zambelli V, Russo I, Barile L, Cornaghi L, Altomare C, Ronchi C, Mostacciuolo G, Lucchetti J, Gobbi M, Latini R, Zaza A.
    Cardiovasc Res; 2014 Oct 01; 104(1):37-48. PubMed ID: 25139747
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
    Iglarz M, Landskroner K, Bauer Y, Vercauteren M, Rey M, Renault B, Studer R, Vezzali E, Freti D, Hadana H, Schläpfer M, Cattaneo C, Bortolamiol C, Weber E, Whitby BR, Delahaye S, Wanner D, Steiner P, Nayler O, Hess P, Clozel M.
    J Cardiovasc Pharmacol; 2015 Nov 01; 66(5):457-67. PubMed ID: 26230396
    [Abstract] [Full Text] [Related]

  • 16. Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats.
    Dahal BK, Kosanovic D, Kaulen C, Cornitescu T, Savai R, Hoffmann J, Reiss I, Ghofrani HA, Weissmann N, Kuebler WM, Seeger W, Grimminger F, Schermuly RT.
    Respir Res; 2011 May 02; 12(1):60. PubMed ID: 21535881
    [Abstract] [Full Text] [Related]

  • 17. Extra domain A-containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody.
    Singerer I, Tempel L, Gruen K, Heiß J, Gutte C, Matasci M, Schrepper A, Bauer R, Berndt A, Jung C, Schulze PC, Neri D, Franz M.
    Cardiovasc Res; 2024 Oct 14; 120(12):1485-1497. PubMed ID: 39023231
    [Abstract] [Full Text] [Related]

  • 18. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
    Wang X, Yang Y, Yang D, Tong G, Lv S, Lin X, Chen C, Dong W.
    J Vasc Surg; 2016 Nov 14; 64(5):1468-1477. PubMed ID: 26527422
    [Abstract] [Full Text] [Related]

  • 19. Chrysin Alleviates Monocrotaline-Induced Pulmonary Hypertension in Rats Through Regulation of Intracellular Calcium Homeostasis in Pulmonary Arterial Smooth Muscle Cells.
    Dong F, Zhang J, Chen X, Zhang S, Zhu L, Peng Y, Guo Z.
    J Cardiovasc Pharmacol; 2020 Jun 14; 75(6):596-602. PubMed ID: 32168153
    [Abstract] [Full Text] [Related]

  • 20. Sulforaphane Improves Redox Homeostasis and Right Ventricular Contractility in a Model of Pulmonary Hypertension.
    Conzatti A, Colombo R, Siqueira R, Campos-Carraro C, Turck P, Luz de Castro A, Belló-Klein A, Sander da Rosa Araujo A.
    J Cardiovasc Pharmacol; 2024 Jun 01; 83(6):612-620. PubMed ID: 38547510
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.